Tag Archives: Dako—

December 2015—Dako announced FDA approval of a test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with Opdivo (nivolumab) for patients with nonsquamous NSCLC.

Oct. 9, 2015—The Food and Drug Administration has approved a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer is likely to respond to Merck’s newly approved anti-PD-1 therapy, pembrolizumbac, marketed as Keytruda. Dako developed the assay, PD-L1 IHC 22C3 pharmDx, in partnership with Merck. Keytruda is approved by the FDA to treat ...

June 2015—Dako, an Agilent Technologies Company, announced a new master collaboration agreement with Amgen. The expanded collaboration will allow both companies to benefit from knowledge sharing within the field of drug-diagnostic research and development and in relation to companion diagnostic products.

April 2015—Dako, an Agilent Technologies company, and Ono Pharmaceutical announced a partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer.

March 2015—Dako, an Agilent Technologies company, and Cell Signaling Technology have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products.

November 2014—Dako, an Agilent Technologies company, announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis. The assay will enable pathology laboratories to integrate the Dako HER2 IQFISH and IQFISH hybridization buffer into their immunohistochemistry workflow.

July 2014—Dako and Merck & Co. will collaborate to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer. The companion diagnostic test coming out of this collaboration will be evaluated as part of the clinical development program from Merck’s investigational anti-PD-1 antibody being studied for the treatment of cancer.

June 2014—Dako added two new antibodies, Anti-CK 8/18 and Anti-TdT, to its portfolio. Anti-CK 8/18 is a rabbit monoclonal antibody cocktail for cytokeratin 8/18 to help classify tumors of unknown origin.

May 2014—Dako added the Jenner-Wright Giemsa stain to its Artisan Link portfolio of automated stains. The stain is designed to provide clear differentiation and detail of the hematopoietic cells in bone marrow tissue samples for the diagnosis of cancer, aplastic anemia, and myelofibrosis.

May 2014—Dako released a paper titled “Immunohistochemistry in Prostate Pathology” that illustrates the significant impact immunohistochemistry can have on diagnostic prostate pathology.